Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial

Sponsor
Johns Hopkins University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04482621
Collaborator
(none)
40
Enrollment
1
Location
2
Arms
22.5
Anticipated Duration (Months)
1.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a a randomized double blind placebo controlled Phase 2 trial with a 12 patient lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a total of 40 patients) to assess efficacy of decitabine in the treatment of critically ill patients with COVID-ARDS. The patients will be randomized in a 1:1 ratio to receive standard of care plus Decitabine or standard of care plus saline based placebo. The primary objective is to determine safety and efficacy of decitabine for COVID-19 ARDS based on clinical improvement on a 6-point clinical scale.

Condition or DiseaseIntervention/TreatmentPhase
Phase 2

Detailed Description

This is a randomized double blind placebo controlled Phase 2 trial with a 12 patient lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a total of 40 patients) to assess efficacy of decitabine in the treatment of critically ill patients with COVID-ARDS. The patients will be randomized in a 1:1 ratio to receive standard of care plus Decitabine or standard of care plus saline based placebo.

Eligible patients will receive decitabine 10 mg/m2 daily for 5 days, 1 cycle only. This is a dose that is half the FDA approved dose for myelodysplastic syndrome (MDS), and using a single cycle.

If less than 2 of the first 6 (treatment arm) patients experience an unacceptable toxicity, defined as any treatment related grade III or higher adverse events, as per section 5.7, within 15 days of initiation of treatment, the drug is safe to continue. If the investigators observe more than 33% patients with unacceptable toxicity, the investigators will pause the accrual pending safety evaluation. After validating safety, the investigators will enroll additional 28 patients towards the primary efficacy endpoint. The investigators will monitor safety throughout the trial by monitoring clinical hematologic, chemistry, vital signs, respiratory parameters, medications, and clinical changes daily as per the schedule of procedures.

Bio samples from peripheral blood mononuclear cell (PBMC) and Mini Bronchoalveolar lavage (BAL) will be collected and stored for secondary analysis and mini BAL will only be collected as an optional sub-study for patient consented to a separate study protocol either at time-point of for-cause clinically indicated bronchoscopy, or for subjects consented to a separate Bronchoalveolar lavage (BAL) interventional study, under the auspices of that protocol. For research bio specimens required after study drug initiation, a window period of +/-24 hours while inpatient, and +/- 4 days for outpatient monitoring will be permitted.

These objectives will allow for the planning of subsequent phase 3 studies, and strengthen implementation of a multi-center randomized trial should this study confirm safety, and suggest efficacy of therapy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a randomized double blind placebo controlled Phase 2 trial with a 12 patient lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a total of 40 patients) to assess efficacy of decitabine in the treatment of critically ill patients with COVID-ARDS. The patients will be randomized in a 1:1 ratio to receive standard of care plus Decitabine or standard of care plus saline based placebo.This is a randomized double blind placebo controlled Phase 2 trial with a 12 patient lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a total of 40 patients) to assess efficacy of decitabine in the treatment of critically ill patients with COVID-ARDS. The patients will be randomized in a 1:1 ratio to receive standard of care plus Decitabine or standard of care plus saline based placebo.
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial
Actual Study Start Date :
Sep 14, 2020
Anticipated Primary Completion Date :
May 1, 2022
Anticipated Study Completion Date :
Aug 1, 2022

Arms and Interventions

ArmIntervention/Treatment
Active Comparator: Decitabine + Standard of Care (SOC)

Study drug Decitabine will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)

Drug: Decitabine
Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants. Decitabine will be administered via Intravenous Administration 10/mg/m^2/day Dosage: 10mg/m^2/day IV day x 5 days (1 cycle only)
Other Names:
  • 5-aza-2'- deoxycytidine
  • DACOGEN
  • Placebo Comparator: Standard of Care (SOC) + Placebo

    Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)

    Other: Placebo Saline
    Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)

    Outcome Measures

    Primary Outcome Measures

    1. Proportion of patients who are alive and free of respiratory failure at day 28 [From the day of randomization to day 28]

      The proportion of patients who are alive and free of respiratory failure at day 28 since start of randomization.

    Secondary Outcome Measures

    1. Safety as assessed by adverse events [Up to 6 weeks]

      Safety assessments using adverse events will be monitored daily while inpatient and weekly through end of study at week 6 once discharged from hospital. They will be monitored and graded using Common Terminology Criteria Adverse Events version 5.0.

    2. Change in oxygenation index [Daily, up to 6 weeks]

      Oxygenation index is used to assess severity of hypoxic respiratory failure. (OI = mean airway pressure (MAP) × Fraction of inspired oxygen (FiO2) × 100÷ partial pressure of oxygen (PaO2). This will be measured daily while subject is on mechanical ventilation up to 6 weeks.

    3. Change in fraction of inspired oxygen [Up to day 29]

      Fraction of inspired oxygen in the oxygen delivery system during hospital stay. Measured at 8 am daily during hospital stay and then weekly until day 29.

    4. Overall survival [Up to 6 weeks]

      Patients status of alive versus death at completion of study follow up period, i.e. 6 weeks from start.

    5. Length of stay in hospital [Till hospital discharge, up to 6 weeks]

      Duration of days from baseline to hospital discharge.

    6. Ventilator free days [Up to 6 weeks]

      For subjects who received mechanical ventilation, total number of days from baseline to end of study at 6 weeks that subject was not on mechanical or non invasive mechanical ventilation.

    7. Time to Polymerase chain reaction (PCR) negativity [Up to 6 weeks]

      If viremic at starting date of decitabine - time from baseline to 1st recorded negative COVID nucleic acid amplification (NAT) based assay, measured in days.

    8. Percentage of patients with National Early Warning Score 2 of 3 or more [Weekly while patient is in hospital, up to 6 weeks]

      Determines the degree of illness of a patient and prompts critical care intervention. This composite score includes Respiratory Rate, Temperature, oxygen Saturation, Blood Pressure, Oxygen inspired and cognitive status. This will be measured at baseline and weekly while patient is in hospital.

    9. All-cause mortality at 28 days since randomization [Daily upto day 28]

      Total number of death at 28 days since day of randomization

    10. Percentage of change of clinical score based on WHO 9-point scale at day 10 from randomization [Daily from randomization to day 10]

      Determine clinical score from randomization date to day 10

    11. Percentage of change of clinical score based on WHO 9-point scale [Weekly while patient is in hospital, up to 6 weeks]

      11. Time from randomization to an at least 2-point decrease in clinical score based on WHO 9-point scale

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. ≥18 years

    2. Use of Intermittent Mechanical Ventilation, non-invasive mechanical ventilation (NIMV) or High Flow Nasal Cannula.

    3. Have ARDS or Acute Lung Injury physiology confirmed by Pao2/Fio2 ratio of < 300

    4. Severe Acute Respiratory Distress Syndrome (SARS) - Coronavirus (CoV-2) determined by lab polymerase chain reaction assay in either upper or lower respiratory tract sampling (e.g. bronchoalveolar lavage or nasopharyngeal swab)

    5. If childbearing age: agree to practice effective birth control from screening until at least 180 days after last dose

    Exclusion Criteria:
    1. Hematologic cytopenias: Absolute Neutrophil Count (ANC) <1500/mm3, Hgb<7.0 and/or platelets <100,000/mm3

    2. Subjects receiving or enrolled in clinical trial for other investigational treatment for SARS- 2-CoV.

    3. Active malignancy, solid tumors, and current or recent chemotherapy

    4. Concomitant use of nonbiologic immunosuppressants (e.g. Janus Kinase (JAK) inhibitors, Bruton's Tyrosine Kinase (BTK) inhibitors)

    5. Active HIV viremia, or any other uncontrolled secondary infection.

    6. Concurrent immunomodulating biologics or use of Palifermin, Dipyrone, Deferiprone

    7. Subjects with severe sepsis with vasopressors or extrapulmonary organ failure:

    8. Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) /alkaline phosphatase (ALK) Phos ≥3x upper limit of normal (ULN) and Total Bilirubin (TBILI) ≥2x ULN; or Creatinine clearance <30 mL/min

    9. Pregnant women or women who are breastfeeding

    10. Any Condition, per opinion of PI that would affect subject safety and/or compliance

    11. Prior hypersensitivity to decitabine

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Johns Hopkins UniversityBaltimoreMarylandUnited States21287

    Sponsors and Collaborators

    • Johns Hopkins University

    Investigators

    • Principal Investigator: Franco D'Alessio, M.D, Johns Hopkins UIniversity

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Johns Hopkins University
    ClinicalTrials.gov Identifier:
    NCT04482621
    Other Study ID Numbers:
    • IRB00247544
    First Posted:
    Jul 22, 2020
    Last Update Posted:
    Feb 24, 2022
    Last Verified:
    May 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Johns Hopkins University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 24, 2022